Clinical Trials Logo
  1. Home
  2. Hyperlipemia
  3. NCT04515927

To Evaluate the Efficacy and Safety of JS002 in HoFH Patients

Hyperlipemia Clinical Trial

Official title:
An Open-label, Single-arm Study Evaluated the Efficacy and Safety of JS002 in Patients With Homozygous Familial Hypercholesterolemia

Clinical Trial Summary

JS002 is a recombinant human anti-PCSK9 monoclonal antibody. This phase II open-label, single-arm study aims to evaluate the efficacy and safety of JS002 in patients with homozygous familial hypercholesterolemia A dose group (450 mg) was set up in this study.Thirty subjects are planned to be enrolled. Each subject required a maximum of 6 weeks of screening, 52 weeks of treatment, and 8 weeks of follow-up.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04515927
Study type Interventional
Source Shanghai Junshi Bioscience Co., Ltd.
Contact
Status Active, not recruiting
Phase Phase 2
Start date August 17, 2020
Completion date July 29, 2022
View Details
See also
  Status Clinical Trial Phase
Completed NCT04382521 - A Text Message Intervention to Promote Health Behaviors in Cardiac Risk Conditions N/A
Not yet recruiting NCT02593487 - Effect of Rosuvastatin Therapy on HDL2 Level Phase 4
Active, not recruiting NCT02697422 - Veteran Peer Coaches Optimizing and Advancing Cardiac Health N/A
Completed NCT04469673 - A Study to Evaluate the Safety, Tolerability and Efficacy of Multiple Doses of JS002 in Patients With Hyperlipidemia.. Phase 1/Phase 2
Recruiting NCT05912296 - A Single and Multiple Ascending Doses Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RBD7022 Phase 1
Active, not recruiting NCT05432544 - Safety and Tolerability of SHR-1918 in Healthy Subjects Phase 1
Completed NCT03950752 - Effect of Consumption of Bagel Without Palm Oil on Postprandial Lipidemia N/A
Not yet recruiting NCT06229548 - A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2053 Phase 1
Completed NCT05532800 - The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia Phase 3
Completed NCT04781114 - The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia Phase 3